For uveal melanoma, the combination of HDAC inhibitors and MEK inhibitors has greater efficacy than monotherapy, as HDAC inhibition suppressing GPCR‐mediated YAP activation and RTK‐driven AKT signaling, which are considered key pathways for rapid resistance for MEK inhibitors [302]. This evidence concerns the gene HDAC9 and uveal melanoma.